Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Equillium, Inc. EQ NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
37/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.00
-51.2%

Equillium, Inc. (EQ) is a Biotechnology company in the Healthcare sector, currently trading at $2.05. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is EQ = $1 (-51.2% upside).

Valuation: EQ trades at a trailing Price-to-Earnings (P/E) of -7.7 (S&P 500 average ~25).

Financials: revenue is $130,000, +14.4%/yr average growth. Net income is $22M (loss), growing at -16.8%/yr. Net profit margin is -17229.2% (negative). Gross margin is 50% (-49.3 pp trend).

Balance sheet: total debt is $719,000 against $29M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 10.32 (strong liquidity). Debt-to-assets is 2.3%. Total assets: $32M.

Analyst outlook: 9 / 11 analysts rate EQ as buy (82%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 58/100 (Partial), Income 10/100 (Fail).

$1.00
▼ 51.22% Downside
Average Price Target
The 12-month price target for Equillium, Inc. is $1.00.

EQ SharesGrow Score Overview

44/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 58/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — EQ

✗
VALUE Fail
10/100
EQ trades at a trailing Price-to-Earnings (P/E) of -7.7 (S&P 500 average ~25). Forward PEG -0.46 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $1, implying -51.2% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
EQ: +14.4%/yr revenue is, -16.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet EQ: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 10.32 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
35/100
EQ: Gross margin is 50% (-49.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
58/100
Analyst outlook: 9 / 11 analysts rate EQ as buy (82%). Analyst consensus target is $1 (-51.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
EQ: Net profit margin is -17229.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.27-2.7
Volume646.12K
Avg Volume (30D)504.23K
Market Cap$72.82M
Beta (1Y)1.74
Share Statistics
EPS (TTM)-0.39
Shares Outstanding$91.88M
IPO Date2018-10-12
Employees35
CEOBruce D. Steel
Financial Highlights & Ratios
Revenue (TTM)$130K
Gross Profit$65K
EBITDA$-23.52M
Net Income$-22.4M
Operating Income$-23.63M
Total Cash$30.28M
Total Debt$719K
Net Debt$-29.56M
Total Assets$31.89M
Price / Earnings (P/E)-5.3
Price / Sales (P/S)560.15
Analyst Forecast
1Y Price Target$1.00
Target High$1.00
Target Low$1.00
Upside-51.2%
Rating ConsensusBuy
Analysts Covering11
Buy 82% Hold 18% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS29446K1060

Price Chart

Track all markets on TradingView
EQ
Equillium, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.27 52WK RANGE 2.70

People Also View

EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 TRVI
TRVI
Trevi Therapeutics, Inc.
$14.27
+1.64%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.77
+0.54%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 MNPR
MNPR
Monopar Therapeutics Inc.
$57.91
-0.02%
 CHRS
CHRS
Coherus BioSciences, Inc.
$1.88
+4.44%
 GRCL
GRCL
Gracell Biotechnologies Inc.
$10.25
+0.05%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.64
-5.04%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message